BAYRY Stock Recent News
BAYRY LATEST HEADLINES
FMC signed a partnership agreement to bring Isoflex Active technology to European markets.
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business amid a high debt burden.
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
Bayer (BAYRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe BioPharma.
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025, taking place in Chicago, IL, from March 29-31, 2025. Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for the treatment of adult pati.
Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer, sending shares of the German pharmaceutical drug giant down Monday.
Here is how Bayer Aktiengesellschaft (BAYRY) and Enhabit (EHAB) have performed compared to their sector so far this year.